Dr. Roth’s professional journey is distinguished by her dual perspective as both a patient and a provider, an experience that uniquely informs her holistic approach to cancer care. Her personal encounter with lymphoma has deepened her commitment to treating not just the disease but the patient as a whole. This patient-centered philosophy resonates in her leadership style and clinical practice, emphasizing comprehensive care that addresses the multifaceted challenges faced by children, adolescents, and young adults undergoing cancer treatment.

Specializing in lymphomas, which encompass a heterogeneous group of hematologic malignancies affecting the immune system, Dr. Roth’s research zeroes in on molecular and cellular mechanisms underlying pediatric lymphoma subtypes, including Hodgkin lymphoma and its rarer variants. Leveraging funding from the National Institutes of Health, her laboratory dissects the pathobiology of these malignancies, aiming to identify molecular drivers that can serve as precision targets for innovative therapies. This translational research bridges laboratory discoveries directly to clinical application, fostering personalized treatment modalities with improved efficacy and reduced toxicity.

Throughout her tenure at Weill Cornell Medicine and NewYork-Presbyterian Hospital prior to joining NYU Langone, Dr. Roth established herself as a pioneering force in the clinical and investigational landscape of lymphoma care for pediatric and young adult populations. She spearheaded and contributed to national clinical trials under the auspices of the Children’s Oncology Group, focusing on refining therapeutic protocols and enhancing survivorship outcomes. These trials emphasize not only maximal disease control but also the amelioration of long-term adverse effects, a critical consideration in pediatric oncology.

In her new capacity at NYU Langone Health, Dr. Roth will oversee the clinical, research, and educational activities within the Division of Pediatric Hematology-Oncology. She intends to expand the division’s capabilities in delivering cutting-edge treatments, including immunotherapies and targeted molecular agents, while increasing patient access to advanced clinical trials. Collaborating closely with Gabriel A. Robbins, MD, medical director of the Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders, Dr. Roth will champion multidisciplinary care models integrating oncology, hematology, pathology, and supportive care disciplines.

Dr. Roth’s leadership arrives at a critical juncture as pediatric oncology navigates the complexities of integrating molecular diagnostics and novel therapeutics into standard care. She aims to harness the full spectrum of ‘omics’ technologies and biomarker-driven studies to tailor therapies according to individual tumor biology, thereby maximizing precision medicine’s promise for young patients with lymphoma. Her vision encompasses both robust bench-to-bedside research pipelines and comprehensive psychosocial support for patients and their families.

Her academic credentials include professorships in the Departments of Pediatrics and Pathology at NYU Langone, reinforcing her expertise in clinical medicine and medical research. As a graduate of the NYU Grossman School of Medicine and a product of prestigious residency and fellowship programs at Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Memorial Sloan Kettering Cancer Center, Dr. Roth embodies a synthesis of clinical acumen and innovative research.

Leadership within the Children’s Oncology Group has been a hallmark of Dr. Roth’s career, where her roles have included vice chair of the Hodgkin Lymphoma Committee. This position entails guiding national collaborative efforts to optimize treatment regimens and improve survival outcomes for children and young adults afflicted with this disease. Her participation underscores a deep commitment to advancing pediatric oncology through cooperative science and evidence-based clinical protocols.

Dr. Roth succeeds Elizabeth A. Raetz, MD, who led the division with distinction for eight years. Dr. Raetz has transitioned to the role of vice chair for clinical affairs in the Department of Pediatrics, continuing her influential presence in pediatric hematology-oncology and in national leukemia and lymphoma research consortia. The leadership handover symbolizes sustained excellence and innovation in the pediatric oncology program at NYU Langone.

NYU Langone Health stands out as a premier academic medical center distinguished by its integrated health system delivering exemplary patient outcomes. Recognized consecutively by Vizient Inc. as the top comprehensive academic medical center in the nation and recently having four clinical specialties ranked number one nationally by U.S. News & World Report, the institution offers an unparalleled ecosystem for cutting-edge cancer research, education, and patient care.

Dr. Roth’s appointment will undoubtedly elevate NYU Langone’s pediatric cancer programs, propelling forward both innovations in lymphoma biology and novel therapeutic interventions. Her vision and expertise promise to transform the lives of countless young patients facing cancer diagnoses, combining rigorous scientific inquiry with compassionate clinical care.

Subject of Research: Pediatric lymphomas, molecular oncology, and clinical trial development in children and young adults with blood cancers.

Article Title: Renowned Pediatric Oncologist Dr. Lisa G. Roth Joins NYU Langone Health to Lead Pediatric Hematology-Oncology Division

News Publication Date: Not specified in the source content.

Web References:
– https://nyulangone.org/doctors/1376704742/lisa-g-roth
– https://nyulangone.org/locations/hassenfeld-childrens-hospital
– https://nyulangone.org/locations/perlmutter-cancer-center
– https://med.nyu.edu/departments-institutes/pediatrics/divisions/pediatric-hematology-oncology

Image Credits: NYU Langone Health

Keywords: Pediatric oncology, lymphoma, Hodgkin lymphoma, pediatric hematology-oncology, clinical trials, molecular oncology, NYU Langone Health, pediatric cancer research, immunotherapy, targeted therapy, pediatric lymphoma clinical care, Children’s Oncology Group

Stegmaier brings a wealth of experience to this leadership role, having been an integral part of Dana-Farber and Boston Children’s Hospital since 2002. Her multifaceted contributions to the institutions include serving as the Vice Chair for Pediatric Oncology Research as well as Co-Director of the Pediatric Hematologic Malignancy Program. Her reputation as a dedicated physician-scientist with a passion for innovative genomic research has earned her recognition both nationally and internationally. Stegmaier’s research has had a profound impact on the understanding and treatment of childhood cancers, particularly acute leukemias and solid tumors.

In her upcoming position, Stegmaier will oversee all aspects of the Pediatric Oncology department, including research, clinical activities, and educational initiatives. This expansive scope highlights the importance of comprehensive leadership, especially in an area that directly affects the lives of young patients and their families. Her strategic vision aims to enhance the cultivation of groundbreaking research and the development of effective therapies tailored for pediatric oncology by leveraging the collaborative environment facilitated between Dana-Farber and Boston Children’s Hospital.

Under her leadership, the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center will continue to be at the forefront of pediatric oncology care, merging scientific research with clinical ingenuity to combat childhood cancer. Stegmaier’s commitment to precision medicine underscores her intention to lead with a patient-first mentality, helping her team identify and implement the most effective treatment plans for various pediatric oncological conditions. The intersection of her clinical and research expertise will enable more individualized approaches to treatment, with the aim of significantly improving outcomes for pediatric patients facing cancer.

Stegmaier’s significant contributions to cancer research have been recognized with numerous awards, including the prestigious NCI Outstanding Investigator Award from the National Cancer Institute. Moreover, her accolades from the Society for Pediatric Research and the A. Clifford Barger Excellence in Mentoring Award reflect her dedication to nurturing the next generation of researchers and clinicians. This emphasis on mentorship is vital in fostering a culture of innovation where new ideas can flourish and evolve within the realm of pediatric hematology and oncology.

Kim Stegmaier is not only a scientist and physician but also a leader who understands the complexities of both managing a department and running a successful research program. Her professional affiliations, including her membership in esteemed organizations such as the Association of American Physicians and the American Society for Clinical Investigation, highlight her stature in the medical community. Additionally, her position on the Board of the American Association for Cancer Research lends further authority to her vision for the future of pediatric oncology.

As a leader, Stegmaier is committed to weaving together research and clinical practice, ensuring that the insights gained from scientific inquiry translate directly into improved treatment protocols for pediatric cancer patients. Her focus on developing and applying genomic technologies illustrates her proactive approach to healthcare, seeking novel therapies and advancing treatment options that prioritally target the genetic underpinnings driving specific cancers in children. This work not only furthers scientific understanding but also paves the way for groundbreaking therapeutic strategies.

Dana-Farber Cancer Institute continues to be heralded as a leading institution in cancer care and research, and Stegmaier’s new role will solidify that reputation further. The Institute’s mission emphasizes the dual focus on research and patient care, and under her stewardship, the Pediatric Oncology department is expected to reinforce this core value. Stegmaier’s efforts will be pivotal in nurturing collaborations that enhance translational research, thereby bridging the gap between laboratory discoveries and clinical applications.

The landscape of pediatric oncology is evolving rapidly, driven by advancements in genomic medicine and precision therapies. Stegmaier’s expertise uniquely positions her to not only adapt to these changes but to serve as a catalyst for innovative approaches that can revolutionize how childhood cancers are treated. Emphasizing collaborative research within the Dana-Farber/Harvard Cancer Center context allows her to amplify resources and talent dedicated to understanding complex pediatric conditions.

Moreover, Stegmaier’s forthcoming initiatives could lead to novel clinical trials that explore uncharted avenues in cancer treatment, with a focus on personalized therapy for young patients. Access to more than 1,100 clinical trials at Dana-Farber provides her with a robust platform to implement research findings effectively and offers patient access to cutting-edge therapies.

As Kimberly Stegmaier transitions into this esteemed leadership role, the anticipation surrounding her contributions is palpable within the oncology community. With remarkable achievements already defining her career, the next chapter promises to be one of profound discovery and impactful patient care. Her leadership stands not only to inspire her colleagues but also serves as a beacon of hope for families experiencing the trials of pediatric cancer.

In summary, Kimberly Stegmaier’s appointment as Chair of Pediatric Oncology represents a significant advancement not only for her career but also for the future of cancer treatment at Dana-Farber and Boston Children’s